In a Pradaxa report published February 28th, 2013, Craig S. Hilliard wrote that in 2010, Pradaxa appeared to be an exciting new drug on the scene as an alternative to warfarin, another anti-coagulant drug that has been around for many years. Pradaxa was initially touted as having similar side effects to warfarin; however, The New York Times has linked over 500 deaths in the U.S. to Pradaxa, and the FDA recently reported approximately 725,000 people have either used or continue to use Pradaxa. Most likely, this continued widespread use is due to specialty and primary physicians being influenced by the manufacturer, Boehringer Ingelheim’s aggressive ad campaign. The Pradaxa manufacturer, Boehringer Ingelheim, is based in Germany.
Originally, Pradaxa was believed to be highly effective in alleviating the stroke risk for atrial fibrillation patients; but now, with so many people experiencing devastating side effects, including hundreds of deaths linked to this drug, the manufacturer’s lawsuits are increasing.
Potential Defective Drug Under Investigation by Other Agencies
Drug Risk, the medication resource center, is in the process of organizing and reporting risks related to the use of Pradaxa. There are new reports by the American College of Cardiology suggesting that Pradaxa appears to carry even greater risks of complications from bleeding than was previously believed; and, in fact, may place individuals at a higher risk for bleeding issues than warfarin. In a report issued by the Institute for Safe Medication Practices, they believe the use Pradaxa carries a risk of bleeding resulting in death that is almost five times greater than the risks related to the use of warfarin.
Oldham & Smith specializes in Florida Mass Tort Litigation for Defective Drugs. We are a team of experts with the experience and determination to pursue justice for you or your loved ones if you have been injured by using Pradaxa. Contact us today for a free consultation.